Targeting Mitochondrially Unhealthy Obesity to Provide an Alternative Mode of Action for Obesity Therapeutics

• Developing a differentiated mode of action from appetite suppression to generate as good efficacy of dual incretins
• Restoring mitochondrial function with a new mode of action to target obesity
• Targeting energy expenditure form switching to carbohydrate
• Exploring metabolic and obesity drivers

Speakers:

Xavier Jacq

Chief Scientific Officer

MitoRx Therapeutics Limited